Drug Trial Radar · NCT06613633
Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC
Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,000
Actual
Start
Sep 1, 2018
Primary completion
Aug 1, 2024
Study completion Feb 20, 2026
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shanghai Chest Hospital; Wuhan TongJi Hospital
- First posted
- Sep 26, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this observational study is to explore the feasibility of stereotactic radiotherapy (SRT) as consolidation therapy for patients with advanced non-small-cell lung cancer who were treated with third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). The investigators plan to explore the time to achieve the best response after EGFR-TKI treatment, the characteristics of the distribution of lesions when the best response is achieved, the feasibility of SRT when the best response is achieved, and the phenotype of disease progression after EGFR-TKI resistance. In summary, this study will provide critical information for exploring the feasibility and optimal design of SRT as consolidation therapy for advanced NSCLC patients treated with third-generation EGFR-TKI, which will further promote the optimization of comprehensive treatment for EGFR-mutant advanced NSCLC.
Conditions
- Third-generation TKI
- NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)Drug
Patients with advanced EGFR-mutated NSCLC who met the inclusion criteria and received third-generation EGFR-TKI (monotherapy or combined with brain radiotherapy)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Best ResponseTime frame: 5 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Wuhan Tongji Hospital
Wuhan, Hubei, China
Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.